Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $3.6 billion.

  • Integra Lifesciences Holdings' Liabilities and Shareholders Equity fell 1031.41% to $3.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $15.4 billion, marking a year-over-year decrease of 372.47%. This contributed to the annual value of $4.0 billion for FY2024, which is 675.4% up from last year.
  • As of Q3 2025, Integra Lifesciences Holdings' Liabilities and Shareholders Equity stood at $3.6 billion, which was down 1031.41% from $3.7 billion recorded in Q2 2025.
  • In the past 5 years, Integra Lifesciences Holdings' Liabilities and Shareholders Equity registered a high of $4.1 billion during Q1 2024, and its lowest value of $3.6 billion during Q3 2025.
  • Its 5-year average for Liabilities and Shareholders Equity is $3.8 billion, with a median of $3.8 billion in 2023.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 946.49% in 2021, then tumbled by 1031.41% in 2025.
  • Integra Lifesciences Holdings' Liabilities and Shareholders Equity (Quarter) stood at $3.8 billion in 2021, then increased by 2.84% to $3.9 billion in 2022, then fell by 2.77% to $3.8 billion in 2023, then increased by 6.75% to $4.0 billion in 2024, then fell by 9.68% to $3.6 billion in 2025.
  • Its last three reported values are $3.6 billion in Q3 2025, $3.7 billion for Q2 2025, and $4.1 billion during Q1 2025.